What does CUSIP 230031106 represent in this 13F holders report?

CUSIP 230031106 is the security identifier for CGEM - Cullinan Therapeutics, Inc. - COMMON STOCK used to aggregate holder disclosures.

How many institutions held CGEM - Cullinan Therapeutics, Inc. - COMMON STOCK in Q1 2023?

97 institutional investors reported CGEM - Cullinan Therapeutics, Inc. - COMMON STOCK for Q1 2023. Use the holders table for investor-level position and value details.

Cullinan Therapeutics, Inc. - COMMON STOCK (CGEM)

CUSIP: 230031106

Q1 2023 13F Holders as of 31 Mar 2023

Security type / class: Equity / COMMON STOCK
Total 13F shares: 32,209,329
Total 13F value: $329,495,842
Share change: -5,489,815
Put/Call ratio: 54%
SEC-reported price per share: $10.23
Number of holders: 97
Value change: -$56,320,751
Number of buys: 47
Number of sells: 45
Shares outstanding: 61,708,871

Security key

230031106

Report period

Q1 2023

Institutions

Top holders

CGEM full security history Ownership snapshot Full 13F holder table Cullinan Therapeutics, Inc. SEC filings Cullinan Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of CGEM - Cullinan Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

MPM BioImpact LLC

Disclosed value leader

MPM BioImpact LLC

Comparable rows

15/15

Latest evidence

31 Dec 2022

13F Lead comparable stake: 12% Showing 1-6 of 15 holder rows.

Quick read

MPM BioImpact LLC leads the comparable SEC ownership view at 12%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens MPM BioImpact LLC's linked filing trail.

Comparable ownership Top 5

MPM BioImpact LLC 12%

BVF INC/IL 12%

CHI Advisors LLC 5.4%

VANGUARD GROUP INC 4.6%

BlackRock Finance, Inc. 4.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
MPM BioImpact LLC	13F Company 13F	12%	$80,689,227 7,648,268 shares	—	31 Dec 2022
BVF INC/IL	13F Company 13F	12%	$79,220,572 7,509,059 shares	—	31 Dec 2022
CHI Advisors LLC	13F Company 13F	5.4%	$35,000,089 3,317,544 shares	—	31 Dec 2022
VANGUARD GROUP INC	13F Company 13F	4.6%	$29,676,782 2,812,965 shares	—	31 Dec 2022
BlackRock Finance, Inc.	13F Company 13F	4.1%	$26,440,569 2,506,215 shares	—	31 Dec 2022
AMERICAN INTERNATIONAL GROUP, INC.	13F Company 13F	2%	$13,061,723 1,238,078 shares	—	31 Dec 2022

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

32,209,329

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q1 2023 Shares	Share Diff	Share Chg %	Q1 2023 value	Q1 2023 value	Value change	Value Chg %